<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579757</url>
  </required_header>
  <id_info>
    <org_study_id>2020-012-GLOB1</org_study_id>
    <nct_id>NCT04579757</nct_id>
  </id_info>
  <brief_title>Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will&#xD;
      evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.&#xD;
      The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will&#xD;
      evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.&#xD;
      The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).&#xD;
&#xD;
      Part 1 will be conducted to determine the recommended phase 2 dose (RP2D) and/or the maximum&#xD;
      tolerated dose (MTD) of surufatinib in combination with tislelizumab in patients with&#xD;
      advanced or metastatic solid tumors who have progressed on, or are intolerant to standard&#xD;
      therapies.&#xD;
&#xD;
      Part 2 will be an open-label, multi-cohort design to evaluate the anti-tumor activity of&#xD;
      surufatinib in combination with tislelizumab in patients with specific types of advanced or&#xD;
      metastatic solid tumors. Patients will receive the RP2D determined in part 1 of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity</measure>
    <time_frame>up to 60 days</time_frame>
    <description>The primary outcome during dose escalation will be the incidence rate of dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The primary outcome of dose expansion will be objective response rate (ORR) in patients with advanced solid tumors when treated with surufatinib in combination with tislelizumab in each cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>the duration between the enrollment date and the first disease progression (PD) or death (whichever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentrations of surufatinib and tislelizumab with blood sampling</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Blood samples will be taken to measure levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety, in subjects, treated with surufatinib and tislelizumab</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Adverse events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The incidence of complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The incidence of partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The period from the date of enrollment to the date when the criteria for complete response or partial response was first measured (first record shall prevail).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The period from date of enrollment to date of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Metastatic Solid Tumor</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Anaplastic Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Surufatinib and tislelizumab (dose escalation_Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 (dose escalation), surufatinib and will be administered orally (PO) once daily (QD) and tislelizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surufatinib and tislelizumab (indication specific_Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, the indication-specific expansion portion of the study, patients will receive surufatinib at the Recommended Phase 2 Dose (RP2D) dose selected in Part 1 with 200 mg tislelizumab IV, Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib and Tislelizumab _ Part 1</intervention_name>
    <description>Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose</description>
    <arm_group_label>Surufatinib and tislelizumab (dose escalation_Part 1)</arm_group_label>
    <other_name>HMPL-012, sulfatinib, BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib and Tislelizumab _ Part 2</intervention_name>
    <description>Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose</description>
    <arm_group_label>Surufatinib and tislelizumab (indication specific_Part 2)</arm_group_label>
    <other_name>HMPL-012, sulfatinib, BGB-A317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent&#xD;
&#xD;
          2. ≥18 years of age&#xD;
&#xD;
          3. Part 1-have evaluable lesions (according to Response Evaluation Criteria in Solid&#xD;
             Tumors version 1.1 [RECIST v1.1])&#xD;
&#xD;
          4. Part 2-have measurable lesions (according to RECIST v1.1)&#xD;
&#xD;
          5. Have a performance status of 0 or 1 on the ECOG scale&#xD;
&#xD;
          6. For female subjects of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement to use a highly effective form(s) of contraception&#xD;
&#xD;
             Dose Escalation:&#xD;
&#xD;
          7. Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
             malignancy of any type,.&#xD;
&#xD;
             Dose Expansion:&#xD;
&#xD;
          8. Histologically or cytologically documented, locally advanced or metastatic:&#xD;
&#xD;
        Cohort A: adenocarcinoma of the colon or rectum that is microsatellite stable. Subjects&#xD;
        must have progressed on, or had intolerable toxicity to, at least 3 prior regimens of&#xD;
        standard chemotherapy.&#xD;
&#xD;
        Cohort B: progressive, low or intermediate grade (grade 1 or grade 2) NETs of thoracic or&#xD;
        GEP origins. Subjects must have radiological documentation of progression of disease in the&#xD;
        last 6 months and must have progressed on at least one line of standard therapy for&#xD;
        metastatic disease.&#xD;
&#xD;
        Cohort C: SCLC that has progressed on standard first line chemotherapy treatment.&#xD;
&#xD;
        Cohort D: adenocarcinoma of the stomach or gastroesophageal junction and have progressed on&#xD;
        at least 2 prior lines of therapy. Tumor stain for PD-L1 by Combined Positive Score (CPS)&#xD;
        ≥5%.&#xD;
&#xD;
        Cohort E: ASPS or UPS. Subjects must have radiological documentation of disease progression&#xD;
        in the last 3 months and have progressed on at least one line of standard therapy or&#xD;
        refused standard frontline cytotoxic chemotherapy.&#xD;
&#xD;
        Cohort F: Anaplastic thyroid cancer that is considered not curable by resection. Patients&#xD;
        with a BRAFV600E mutation must have previously been treated with 1 line of systemic therapy&#xD;
        with a BRAF-targeted therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adverse events (AEs) due to previous anti-tumor therapy has not recovered to Common&#xD;
             Terminology Criteria for Adverse Event (CTCAE) ≤Grade 1;&#xD;
&#xD;
          2. Part 2 subjects with CRC , NETs and STS any previous treatment with anti-PD-1, anti&#xD;
             PD-L1/L2 antibodies, anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4)&#xD;
             antibody, or any other antibody acting on T cell costimulatory or checkpoint pathway;&#xD;
&#xD;
          3. Previous treatment with surufatinib;&#xD;
&#xD;
          4. Uncontrollable hypertension;&#xD;
&#xD;
          5. History or presence of a serious hemorrhage (&gt;30 ml within 3 months), hemoptysis (&gt;5&#xD;
             ml blood within 4 weeks) or life threatening thromboembolic event within 6 months;&#xD;
&#xD;
          6. Clinically significant cardiovascular disease;&#xD;
&#xD;
          7. Any clinically significant active infection, including, but not limited to, known&#xD;
             human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          8. Brain metastases and/or leptomeningeal disease and/or spinal cord compression&#xD;
             untreated with surgery and/or radiotherapy, and without clinical imaging evidence of&#xD;
             SD for 14 days or longer; subjects requiring steroids within 4 weeks prior to start of&#xD;
             study treatment will be excluded;&#xD;
&#xD;
          9. Active autoimmune diseases or history of autoimmune diseases that may relapse with the&#xD;
             following exceptions:&#xD;
&#xD;
               1. Controlled Type 1 diabetes&#xD;
&#xD;
               2. Hypothyroidism (provided it is managed with hormone-replacement therapy only)&#xD;
&#xD;
               3. Controlled celiac disease&#xD;
&#xD;
               4. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or&#xD;
                  alopecia)&#xD;
&#xD;
               5. Any other disease that is not expected to recur in the absence of external&#xD;
                  triggering factors.&#xD;
&#xD;
         10. Arterial thrombosis or thromboembolic events (including stroke and/or transient&#xD;
             ischemic attack) within 12 months prior to first dosing;&#xD;
&#xD;
         11. History of deep venous thrombosis within 6 months;&#xD;
&#xD;
         12. Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
         13. Any condition by which investigators judge patients not suitable to participate in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Callahan</last_name>
    <phone>973-826-5578</phone>
    <email>lesliec@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Tucci</last_name>
    <phone>973-786-2634</phone>
    <email>Christucci@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology Associated, PC-HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <email>julie.klinker@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sudhir Manda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Yeung</last_name>
      <email>ruyeung@coh.org</email>
    </contact>
    <investigator>
      <last_name>Daneng Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hege</last_name>
      <email>Jennifer.hege@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Allen Cohn, MD</last_name>
      <phone>(303)388-4876</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Davis</last_name>
      <email>erin.t.davis@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Conor Steuer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Salaman</last_name>
      <email>salamanl@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Sujana Movva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Magdinec</last_name>
      <phone>216-286-3369</phone>
      <email>Megan.Magdinec@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amr Mohamed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Walsh</last_name>
      <email>Jennifer.Walsh4@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Eads, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health - Upstate (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Moore</last_name>
      <phone>864-455-3600</phone>
      <email>Jean.moore@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Ki Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mantegani</last_name>
      <phone>615-329-7289</phone>
      <email>Jennifer.Mantegani@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Dumont</last_name>
      <phone>615-936-5173</phone>
      <email>anna.dumont@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Satya Das, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Bravo</last_name>
      <phone>214-545-3890</phone>
      <email>FBravo@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Wright</last_name>
      <phone>469-324-8318</phone>
      <email>jennifer.wright2@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>S</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrew S Paulson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-413-1760</phone>
      <email>nori.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Richard Richey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercy F David, RN</last_name>
      <email>MFDavid@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Arvind Dasari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Gatlin</last_name>
      <email>frances.gatlin@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

